Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Fifth Annual JMP Securities Research Conference on March 9, 2006 in San Francisco, California. The Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin mesylate) tablets in Mexico to Pfizer, S.A. de C.V and the acquisition of expanded worldwide rights for the Company's lead clinical candidate, Ramoplanin.
